Antibody gene therapy: Getting closer to clinical application?

Current Gene Therapy

Volumn 13, Issue 4, 2013, Pages 282-290

  Guijarro Muñoz, Irene ^a   Compte, Marta ^a   Alvarez Vallina, Luis ^a   Sanz, Laura ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Antibody; Cell factory; Gene therapy; Immunotherapy; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; CD80 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DIABODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1B12 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; INTERLEUKIN 6; LAMININ RECEPTOR; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THYROGLOBULIN ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR ANTIBODY V65;

ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ARTICLE; BREAST CANCER; COCAINE DEPENDENCE; COLON CANCER; COLON CARCINOMA; FIBROSARCOMA; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CANCER; LUNG EDEMA; LUNG METASTASIS; MELANOMA; NEURAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OVARY CANCER; PLAGUE; PROSTATE CANCER; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SARCOMA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; TOBACCO DEPENDENCE; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES; GENETIC THERAPY; HUMANS; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 84888125464     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/15665232113139990025     Document Type: Article

References (75)

1. Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012; 899:1-26.
2. Sanz L, Compte M, Guijarro-Muñoz I, Álvarez-Vallina L. Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Ther 2012; 19(1): 1-7.
3. Savelkoul HF, Vossen AC, Breedland EG, Tibbe GJ. Semi-preparative purification and validation of monoclonal antibodies for immunotherapy in mice. J Immunol Methods 1994; 172(1): 33-42.
4. Okada N, Miyamoto H, Yoshioka T, et al. Cytomedical therapy forIgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(L)lysinealginate membrane. Biochim Biophys Acta 1997; 1360(1): 53-63.
5. Pelegrin M, Marin M, Noël D, et al. Systemic long-term deliveryof antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Ther 1998; 5(6): 828-34.
6. Dautzenberg H, Schuldt U, Grasnick G, et al. Development ofcellulose sulfate-based polyelectrolyte complex microcapsules for medical applications. Ann N Y Acad Sci 1999; 875: 46-63.
7. Pelegrin M, Marin M, Oates A, et al. Immunotherapy of a viraldisease by in vivo production of therapeutic monoclonal antibodies. Hum. Gene Ther 2000; 11(10): 1407-15.
8. Noël D, Pelegrin M, Marin M, et al. In vitro and in vivo secretionof cloned antibodies by genetically modified myogenic cells. Hum Gene Ther 1997; 8(10): 1219-29.
9. Noël D, Pelegrin M, Brockly F, Lund AH, Piechaczyk M. Sus-tained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts. J Invest Dermatol 2000; 115(4): 740-5.
10. Noël D, Dazard J-E, Pelegrin M, Jacquet C, Piechaczyk M. Skin asa potential organ for ectopic monoclonal antibody production. J Invest Dermatol 2002; 118(2):288-94.
11. Sanhadji K, Grave L, Touraine JL, et al. Gene transfer of anti-gp41antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. AIDS 2000; 14(18): 2813-22.
12. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L.Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010; 28(7): 355-62.
13. Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy:teaching old «magic bullets» new tricks. Trends Immunol 2004; 25(2): 85-91.
14. Sanz L, Qiao J, Vile RG, Alvarez-Vallina L. Antibody engineering,virus retargeting and cellular immunotherapy: one ring to rule them all? Curr Gene Ther 2005; 5(1): 63-70.
15. Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Antibodyengineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 2005; 26(6): 641-8.
16. Sanz L, García-Bermejo L, Blanco FJ, et al. A novel cell bindingsite in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J 2003; 22(7): 1508-17.
17. Sanz L, Kristensen P, Blanco B, et al. Single-chain antibody-basedgene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther 2002; 9(15): 1049-53.
18. Sánchez-Arévalo Lobo VJ, Cuesta ÁM, Sanz L, et al. Enhancedantiangiogenic therapy with antibody-collagen XVIII NC1 domainfusion proteins engineered to exploit matrix remodeling events. Int J Cancer 2006; 119(2): 455-62.
19. Afanasieva TA, Wittmer M, Vitaliti A, Ajmo M, Neri D, KlemenzR. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther 2003; 10(21): 1850-9.
20. Tuve S, Chen B-M, Liu Y, et al. Combination of tumor site-locatedCTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007; 67(12): 5929-39.
21. Kontermann R. Dual targeting strategies with bispecific antibodies. MAb 2012; 4(2).
22. Blanco B, Holliger P, Vile RG, Álvarez-Vallina L. Induction ofhuman T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from genemodified bystander cells. J Immunol 2003; 171(2): 1070-7.
23. Compte M, Blanco B, Serrano F, et al. Inhibition of tumor growthin vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14(4): 380-8.
24. Compte M, Cuesta AM, Sánchez-Martín D, et al. Tumor immuno-therapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009; 27(3): 753-60.
25. Compte M, Alonso-Camino V, Santos-Valle P, et al. Factoryneovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Ther 2010; 17(6): 745-51.
26. Compte M, Nuñez-Prado N, Sanz L, Álvarez-Vallina L. Immuno-therapeutic organoids: A new approach to cancer treatment. Biomatter 2013; 3(1).
27. Kasuya K, Shimazu M, Suzuki M, Itoi T, Aoki T, Tsuchida A.Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer. Int J Mol Med 2010; 25(2): 209-15.
28. Frank RT, Edmiston M, Kendall SE, et al. Neural stem cells as anovel platform for tumor-specific delivery of therapeutic antibodies. Plos One 2009; 4(12): e8314.
29. Joseph A, Zheng JH, Chen K, et al. Inhibition of in vivo HIV infec-tion in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 2010; 84(13): 6645-53.
30. Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: itsimplications and circumvention strategies. Curr Gene Ther 2011; 11(4): 307-20.
31. Mingozzi F, High KA. Therapeutic in vivo gene transfer for geneticdisease using AAV: progress and challenges. Nat Rev Genet 2011; 12(5): 341-55.
32. Whittington HA, Ashworth LJ, Hawkins RE. Recombinant adeno-viral delivery for in vivo expression of scFv antibody fusion proteins. Gene Ther 1998; 5(6): 770-7.
33. Noël D, Pelegrin M, Kramer S, Jacquet C, Skander N, PiechaczykM. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther 2002; 13(12): 1483-93.
34. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. Gen-eration of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 2002; 76(17): 8769-75.
35. Arafat WO, Gómez-Navarro J, Buchsbaum DJ, et al. Effectivesingle chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther 2002; 9(4): 256-62.
36. Fang J, Qian J-J, Yi S, et al. Stable antibody expression at thera-peutic levels using the 2A peptide. Nat Biotechnol 2005; 23(5): 584-90.
37. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediated genetransfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15(8): 901-6.
38. Balazs AB, West AP Jr. Antibody gene transfer for HIV immuno-prophylaxis. Nat Immunol 2013; 14(1): 1-5.
39. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D.Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481(7379): 81-4.
40. Escoffre J-M, Zeghimi A, Novell A, Bouakaz A. In-vivo genedelivery by sonoporation: recent progress and prospects. Curr Gene Ther 2012; 12(5): 417-22.
41. Murakami T, Sunada Y. Plasmid DNA gene therapy by electropo-ration: principles and recent advances. Curr Gene Ther 2011; 11(6): 447-56.
42. Tjelle TE, Corthay A, Lunde E, et al. Monoclonal antibodies pro-duced by muscle after plasmid injection and electroporation. Mol Ther 2004; 9(3): 328-36.
43. Perez N, Bigey P, Scherman D, Danos O, Piechaczyk M, PelegrinM. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther 2004; 2(1): 2.
44. Kitaguchi K, Toda M, Takekoshi M, Maeda F, Muramatsu T, Mu-rai A. Immune deficiency enhances expression of recombinant human antibody in mice after nonviral in vivo gene transfer. Int J Mol Med 2005; 16(4): 683-8.
45. Yamazaki T, Nagashima M, Ninomiya D, et al. Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids. Jpn J Infect Dis 2011; 64(1): 40-9.
46. Acarregui A, Murua A, Pedraz JL, Orive G, Hernández RM. Aperspective on bioactive cell microencapsulation. BioDrugs 2012; 26(5): 283-301.
47. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit:poised at the clinical crossroads. Mol Ther 2012; 20(4): 699-708.
48. Kay MA. State-of-the-art gene-based therapies: the road ahead. NatRev Genet 2011; 12(5): 316-28.
49. Tolmachov OE. Building mosaics of therapeutic plasmid genevectors. Curr Gene Ther 2011; 11(6): 466-78.
50. Noël D, Pelegrin M, Brockly F, Lund AH, Piechaczyk M. Sus-tained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts. J Invest Dermatol 2000; 115(4): 740-5.
51. Lamikanra A, Myers KA, Ferris N, Mitrophanous KA, CarrollMW. In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies. Gene Ther 2005; 12(12): 988-98.
52. Jiang M, Shi W, Zhang Q, et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 2006; 12(20 Pt 1): 6179-85.
53. Shi J, Liu Y, Zheng Y, et al. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice. Cancer Res 2006; 66(24): 11946-53.
54. Fang J, Yi S, Simmons A, et al. An antibody delivery system forregulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 2007; 15(6): 1153-9.
55. Skaricic D, Traube C, De B, et al. Genetic delivery of an anti-RSVantibody to protect against pulmonary infection with RSV. Virology 2008; 378(1): 79-85.
56. Zuber C, Mitteregger G, Schuhmann N, et al. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol 2008; 89(Pt 8): 2055-61.
57. Pereboev A, Borisevich V, Tsuladze G, et al. Genetically deliveredantibody protects against West Nile virus. Antiviral Res 2008; 77(1): 6-13.
58. Vigna E, Pacchiana G, Mazzone M, et al. «Active» cancer immu-notherapy by anti-Met antibody gene transfer. Cancer Res 2008; 68(22): 9176-83.
59. De BP, Hackett NR, Crystal RG, Boyer JL. Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. Mol Ther 2008; 16(1): 203-9.
60. Ho DT, Wykoff-Clary S, Gross CS, et al. Growth inhibition of anestablished A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer Gene Ther 2009; 16(2): 184-94.
61. Liu X, Wu J, Zhang S, Li C, Huang Q. Novel strategies to augmentgenetically delivered immunotoxin molecular therapy for cancer therapy. Cancer Gene Ther 2009; 16(11): 861-72.
62. Sofer-Podesta C, Ang J, Hackett NR, et al. Adenovirus-mediateddelivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun 2009; 77(4): 1561-8.
63. Van Blarcom TJ, Sofer-Podesta C, Ang J, Boyer JL, Crystal RG,Georgiou G. Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Gene Ther 2010; 17(7): 913-21.
64. Watanabe M, Boyer JL, Hackett NR, Qiu J, Crystal RG. Geneticdelivery of the murine equivalent of bevacizumab (avastin), ananti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice. Hum Gene Ther 2008; 19(3): 300-10.
65. Watanabe M, Boyer JL, Crystal RG. Genetic delivery of bevacizu-mab to suppress vascular endothelial growth factor-induced highpermeability pulmonary edema. Hum. Gene Ther 2009; 20(6): 598-610.
66. Watanabe M, Boyer JL, Crystal RG. AAVrh.10-mediated geneticdelivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther 2010; 17(8): 1042-51.
67. Wang G, Qiu J, Wang R, et al. Persistent expression of biologicallyactive anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther 2010; 17(8): 559-70.
68. Liu Y, Tuve S, Persson J, et al. Adenovirus-mediated intratumoralexpression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer Gene Ther 2011; 18(6): 407-18.
69. Rosenberg JB, Hicks MJ, De BP, et al. AAVrh.10-mediated ex-pression of an anti-cocaine antibody mediates persistent passiveimmunization that suppresses cocaine-induced behavior. Hum Gene Ther 2012; 23(5): 451-9.
70. Mao Y, Kiss S, Boyer JL, et al. Persistent suppression of ocularneovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum Gene Ther 2011; 22(12): 1525-35.
71. Lv F, Qiu Y, Zhang Y, et al. Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice. Cancer Lett 2011; 302(2): 119-27.
72. Li M, Wu Y, Qiu Y, et al. 2A peptide-based, lentivirus-mediatedanti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice. Mol Ther 2012; 20(1): 46-53.
73. Han T, Abdel-Motal UM, Chang D-K, et al. Human anti-CCR4minibody gene transfer for the treatment of cutaneous T-cell lymphoma. Plos One 2012; 7(9): e44455.
74. Yang J, Pattanayak A, Song M, et al. Muscle-directed anti-Asingle-chain antibody delivery via AAV1 reduces cerebral A load in an Alzheimer's disease mouse model. J Mol Neurosci 2013; 49(2): 277-88.
75. Hicks MJ, Rosenberg JB, De BP, et al. AAV-directed persistentexpression of a gene encoding anti-nicotine antibody for smoking cessation. Sci Transl Med 2012; 4(140): 140-87.